A Randomized Phase II Trial of Hypo-fractionated Intensity-Modulated Radiation Therapy IMRT Utilizing 2.5 Gy/Fraction VS. Standard-Fractionated IMRT, Concurrent with Carboplatin/Paclitaxel and Followed by Consolidation Durvalumab, for Subjects with Stage III Non-Small Cell Lung Cancer

Brief Summary

Type:
Lung Cancers

Study Type:
Treatment

Phase:
II

ClinicalTrials.gov Identifier:
NCT04992780

Study #:
STUDY00147487

Start Date:
Feb 24, 2022

Full Details and Eligibility at clinicaltrials.gov

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below.

ClinicalTrials.gov ID: NCT04992780

View Complete Trial Details & Eligibility at ClinicalTrials.gov